Eton posted GAAP net income of $1.5 million for the quarter, compared with a GAAP net loss of $0.6 million in the year-ago period. On a non-GAAP basis, net income was $5.4 million versus $0.7 million a year earlier. Adjusted EBITDA was $6.2 million, or 29% of revenue, up from $2.1 million, or 18%, in the prior-year quarter.Adjusted gross profit was $15.5 million, or 73% of revenue, compared with $6.8 million, or 59%, a year earlier. Gruber attributed the improvement to favorable product mix and manufacturin ...

Eton Pharmaceuticals (NasdaqGM:ETON) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsDavid Krempa - Chief Business OfficerIpek Erdogan-Trinkaus - Chief Commercial OfficerJames Gruber - CFOSean Brynjelsen - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research Analyst of HealthcareMadison El-Saadi - Healthcare Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity research AnalystOperatorGood afternoon, and welcome to the Eton Pharmaceuticals f ...

Eton Pharmaceuticals (NasdaqGM:ETON) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsDavid Krempa - Chief Business OfficerIpek Erdogan-Trinkaus - Chief Commercial OfficerJames Gruber - CFOSean Brynjelsen - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research Analyst of HealthcareMadison El-Saadi - Healthcare Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity research AnalystOperatorGood afternoon, and welcome to the Eton Pharmaceuticals f ...

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported fourth quarter product revenue of $21.3 million, an increase of 83% year-over-year, driven by strong performance from Alkindi Sprinkles and new products Increlex, Galzin, and KHINDIVI [5][38] - The adjusted EBITDA margin improved to 29%, up from 18% in the prior year period, indicating significant progress in profitability [6][45] - GAAP net income for the quarter was $1.5 million, compared to a net loss of $0.6 million in the prior year [46][47] Business Line Data and Key Metrics Changes - The launch of Increlex, Galzin, and KHINDIVI contributed significantly to revenue growth, with both Increlex and Galzin exceeding initial expectations [5][38] - Alkindi Sprinkles continued to perform strongly, contributing to the overall revenue increase [5][38] - The company expects adjusted gross margins to be comfortably above 70% for the full year, with potential to reach between 75% and 80% in the coming years [39][40] Market Data and Key Metrics Changes - The addressable market for DESMODA includes both pediatric and adult patients, expanding the potential patient base significantly beyond initial estimates [10][11] - The company anticipates a peak sales forecast of $30 million to $50 million for DESMODA, with initial demand showing strong traction [10][11] Company Strategy and Development Direction - Eton aims to build the largest rare disease portfolio in the U.S. and has set new long-term goals, including reaching a $200 million revenue run rate by the end of 2027 [32][33] - The company plans to optimize the distribution model for HEMANGEOL to improve operational efficiency and margin performance [20][21] - Eton is focused on maintaining profitability while pursuing growth, with a target of achieving a 50% adjusted EBITDA margin by 2028 [34][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for existing products and the successful integration of new acquisitions, including HEMANGEOL and DESMODA [31][60] - The company expects to generate significant operating cash flow throughout 2026 and beyond, indicating a positive outlook for financial health [48] Other Important Information - Eton's acquisition of HEMANGEOL was completed for $14 million in cash, avoiding dilution or incremental debt, which is expected to enhance earnings [24] - The company is preparing for a pilot initiative targeting adult endocrinologists for DESMODA, assessing the opportunity over the next 90 days [10] Q&A Session Summary Question: Growth assumptions for HEMANGEOL - Management believes that increasing patient adoption will be driven by a zero copay initiative and enhanced awareness efforts [50][51] Question: DESMODA's pace to peak sales - The launch of DESMODA has gone well, with expectations for quicker peak sales compared to previous products due to the specific unmet need it addresses [53][54] Question: Cash flow conversion from EBITDA in 2026 - The company anticipates being firmly in positive operating cash flow territory in 2026, with some timing considerations for supplier commitments [56][57] Question: $200 million run rate by end of 2027 - Management is confident that the existing product portfolio, including HEMANGEOL and DESMODA, will contribute significantly to achieving this goal [59][60]

Financial Data and Key Metrics Changes - Third quarter product revenue was $22.5 million, an increase of 129% year-over-year and up 19% compared to the second quarter, marking the 19th consecutive quarter of sequential product revenue growth [4][25] - Adjusted EBITDA for the third quarter was $2.9 million, compared to $2.0 million in the prior year period [29] - The company reported a net loss of $1.9 million for the quarter, compared to net income of $0.6 million in the prior year period [29] Business Line Data and Key Metrics Changes - Alkindi Sprinkle and Coagadex drove strong year-over-year growth, alongside contributions from recently acquired products Increlex and Galzin [4] - Increlex's revenue and patient count continue to exceed original projections, with a net active patient count remaining around 100 [6][8] - Galzin now has over 200 active patients, surpassing the original year-end target for 2025 [16] Market Data and Key Metrics Changes - The company experienced a less favorable payer mix in the third quarter, resulting in lower revenue per patient compared to the second quarter [26] - The company expects U.S. product sales to continue to grow sequentially in the fourth quarter compared to the third quarter, despite some non-recurring revenue from Increlex-related sales [26] Company Strategy and Development Direction - Eton is focused on expanding its product portfolio through strategic acquisitions, with $37 million in cash available for financing [23] - The company aims to harmonize the U.S. and EU definitions of severe primary IGF-1 deficiency to potentially increase the Increlex market opportunity fivefold [11] - Eton plans to launch ET-600, an oral solution for treating central diabetes insipidus, with a PDUFA date set for February 25, 2026 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth opportunities for Increlex, Alkindi, and Kindivi, with expectations for continued strong revenue growth [24] - The company anticipates significant growth in 2026, driven by product launches and pipeline developments [24] Other Important Information - Adjusted gross profit was $10.2 million in the third quarter, representing an adjusted gross margin of 45%, impacted by Increlex ex-U.S.-related costs [27] - The company generated $12 million in cash from operations during the quarter [5][30] Q&A Session Summary Question: Can you provide pro-forma gross margins for the core U.S. business excluding non-recurring revenue? - Adjusted gross margins without Increlex ex-U.S. activity would be over 70% for the quarter [31] Question: What are the drivers behind the sequential revenue growth for Alkindi? - The focus of the sales force on pediatric endocrinology and increased physician comfort with the product are key drivers [32] Question: What is the status of the Increlex U.S. registry? - The registry will take place at U.S. sites, separate from those in the global registry [36] Question: What is the company's approach to business development opportunities? - The company is in late-stage discussions for two ultra-rare disease products and expects to close transactions soon [38] Question: What are the reasons for patient discontinuation on Increlex? - Discontinuation is primarily due to patients aging out, which is expected and normal [40]